Evidence map›Paper›PMID 39224803›Full record

ReviewFrontiers in oncology2024

Integrating frontiers: a holistic, quantum and evolutionary approach to conquering cancer through systems biology and multidisciplinary synergy.

Matheus Correia Casotti, Débora Dummer Meira, Aléxia Stefani Siqueira Zetum, Camilly Victória Campanharo, Danielle Ribeiro Campos da Silva, Giulia Maria Giacinti, Iris Moreira da Silva, João Augusto Diniz Moura, Karen Ruth Michio Barbosa, Lorena Souza Castro Altoé and 14 more

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Matheus Correia Casotti *Núcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Débora Dummer Meira *Núcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Aléxia Stefani Siqueira ZetumNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Camilly Victória CampanharoNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Danielle Ribeiro Campos da SilvaNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Giulia Maria GiacintiNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Iris Moreira da SilvaNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
João Augusto Diniz MouraLaboratório de Oncologia Clínica e Experimental, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Karen Ruth Michio BarbosaNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Lorena Souza Castro AltoéNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Lorena Souza Rittberg MauricioLaboratório de Oncologia Clínica e Experimental, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Luíza Santa Brígida de Barros GóesGrupo de Bioanalítica, Microfabricação e Separações (BioMicS), Universidade de São Paulo (USP), São Carlos, SP, Brazil.
Lyvia Neves Rebello AlvesNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Sarah Sophia Guedes LinharesLaboratório de Estudos Neuroquímicos, Universidade Federal do Rio Grande do Norte (UFRN), Natal, RN, Brazil.
Vinícius do Prado VentorimNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Yasmin Moreto GuaitoliniNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Eldamária de Vargas Wolfgramm Dos SantosNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Flavia Imbroisi Valle ErreraNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Sonia GroismanInstituto de Biologia Roberto Alcântara Gomes (IBRAG), Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil.
Elizeu Fagundes de CarvalhoInstituto de Biologia Roberto Alcântara Gomes (IBRAG), Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil.
Flavia de PaulaNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.
Marcelo Victor Pires de SousaBright Photomedicine, Tergos Pesquisa E Ensino S.A., São Paulo, SP, Brazil.
Pierre Basílio Almeida FechineGroup of Chemistry of Advanced Materials (GQMat), Department of Analytical Chemistry and Physical-Chemistry, Federal University of Ceará (UFC), Fortaleza, CE, Brazil.
Iuri Drumond LouroNúcleo de Genética Humana e Molecular, Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer therapy is facing increasingly significant challenges, marked by a wide range of techniques and research efforts centered around somatic mutations, precision oncology, and the vast amount of big data. Despite this abundance of information, the quest to cure cancer often seems more elusive, with the "war on cancer" yet to deliver a definitive victory. A particularly pressing issue is the development of tumor treatment resistance, highlighting the urgent need for innovative approaches. Evolutionary, Quantum Biology and System Biology offer a promising framework for advancing experimental cancer research. By integrating theoretical studies, translational methods, and flexible multidisciplinary clinical research, there's potential to enhance current treatment strategies and improve outcomes for cancer patients. Establishing stronger links between evolutionary, quantum, entropy and chaos principles and oncology could lead to more effective treatments that leverage an understanding of the tumor's evolutionary dynamics, paving the way for novel methods to control and mitigate cancer. Achieving these objectives necessitates a commitment to multidisciplinary and interprofessional collaboration at the heart of both research and clinical endeavors in oncology. This entails dismantling silos between disciplines, encouraging open communication and data sharing, and integrating diverse viewpoints and expertise from the outset of research projects. Being receptive to new scientific discoveries and responsive to how patients react to treatments is also crucial. Such strategies are key to keeping the field of oncology at the forefront of effective cancer management, ensuring patients receive the most personalized and effective care. Ultimately, this approach aims to push the boundaries of cancer understanding, treating it as a manageable chronic condition, aiming to extend life expectancy and enhance patient quality of life.

Indexed as

biological evolutioncarcinogenesischaos and quantum theorydynamicsneoplasmstranslational science

Identifiers

PMID39224803
PMCPMC11367711

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.